Sapien AI Corp., a data labeling company, today announced it raised $5 million in a seed funding round to build out its service of providing high-quality annotation and labeling for training ...
LONDON, November 25, 2024--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced one-year data highlighting the continued outstanding performance of its SAPIEN 3 Ultra RESILIA valve. The ...
During valve-in-valve TAVI procedures using the Sapien 3 balloon-expandable valve (Edwards Lifesciences) as the second prosthesis, downsizing and underexpansion are frequently observed, particularly ...
WASHINGTON -- A slight tweak to the Sapien 3 turned it into a device usable for transcatheter mitral valve replacement (TMVR), a first-in-human experience showed. By adding a new sealing skirt, ...
Edwards Lifesciences has received CE Mark approval for expanding the use of the Sapien 3 transcatheter heart valve to patients with severe, symptomatic aortic stenosis at intermediate risk for ...
Edwards Lifesciences Corporation EW recently launched the SAPIEN 3 Ultra RESILIA valve post the FDA approval of the same. The SAPIEN 3 Ultra RESILIA valve comprises the breakthrough RESILIA tissue ...
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback